Literature DB >> 12042029

Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension.

Shiro Kato1, Hiroyuki Sugimura, Izumi Kishiro, Masaru Machida, Hidehiko Suzuki, Noboru Kaneko.   

Abstract

The effect of long-term prostaglandin E(1) (PGE(1)) aerosol was investigated in rats with chronic pulmonary hypertension induced by monocrotaline (MCT). Six-week-old Sprague-Dawley rats were separated into groups of 6 and administered 1 mL of saline (group A) or 60 mg / kg of MCT. The MCT-treated mice were then administered either nothing (group B) or 5 mL of PGE(1) (4 microg/mL) via a nebulizer every day for 1 week (group C), 2 weeks (group D), 3 weeks (group E), or 4 weeks (group F) after MCT injection. The pulmonary artery medial wall thickness was measured and the weight ratio of the right ventricle to the intraventricular septum plus the left ventricle (RV ratio) was determined 1 month after saline or MCT injection. Leukocytes positive for the activation markers CD18, CD49d, CD62L were determined in each group every week for 1 month. The pulmonary artery medial wall thickness and RV ratio gradually decreased in proportion to the duration of PGE(1) inhalation. In groups E and F, the level of CD62L-positive leukocytes gradually decreased after MCT injection in proportion to the duration of PGE(1) inhalation. We conclude that long-term inhalation of PGE(1) is very useful therapy in chronic pulmonary hypertension and that the antileukocyte effect of PGE(1) is associated with the suppression of CD62L-positive leukocytes at an early stage of progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042029     DOI: 10.1080/01902140252964357

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  7 in total

1.  Toxicity of prolonged high dose inhaled PGE1 in ventilated neonatal pigs.

Authors:  Beena G Sood; Elizabeth J Dawe; Krishna Rao Maddipati; Monica Malian; Xinguang Chen; Robert Galli; Raja Rabah
Journal:  Pulm Pharmacol Ther       Date:  2008-02-06       Impact factor: 3.410

2.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

3.  Effect of prostaglandin E1 inhalation on pulmonary hypertension following corrective surgery for congenital heart disease.

Authors:  Chun-Yan Zhang; Zeng-Shan Ma; Long-Le Ma; Le-Xin Wang
Journal:  Exp Clin Cardiol       Date:  2013

4.  Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.

Authors:  Leila Gobejishvili; Smita Ghare; Rehan Khan; Alexander Cambon; David F Barker; Shirish Barve; Craig McClain; Daniell Hill
Journal:  Clin Immunol       Date:  2015-09-25       Impact factor: 3.969

5.  Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial.

Authors:  Beena G Sood; Virginia Delaney-Black; Jacob V Aranda; Seetha Shankaran
Journal:  Pediatr Res       Date:  2004-08-04       Impact factor: 3.756

6.  Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.

Authors:  Soni Pullamsetti; Stefanie Krick; Hüseyin Yilmaz; Hossein Ardeschir Ghofrani; Christian Schudt; Norbert Weissmann; Beate Fuchs; Werner Seeger; Friedrich Grimminger; Ralph Theo Schermuly
Journal:  Respir Res       Date:  2005-11-01

7.  Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials.

Authors:  Beena G Sood; Martin Keszler; Meena Garg; Jonathan M Klein; Robin Ohls; Namasivayam Ambalavanan; C Michael Cotten; Monica Malian; Pablo J Sanchez; Satyan Lakshminrusimha; Leif D Nelin; Krisa P Van Meurs; Rebecca Bara; Shampa Saha; Abhik Das; Dennis Wallace; Rosemary D Higgins; Seetha Shankaran
Journal:  Trials       Date:  2014-12-12       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.